Pharmacology and antifungal properties of anidulafungin, a new echinocandin

Pharmacotherapy

Volumn 29, Issue 1, 2009, Pages 17-30

  Estes, Kristina E ^a   Penzak, Scott R ^a   Calis, Karim Anton ^a   Walsh, Thomas J ^b  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Anidulafungin; Candidemia; Echinocandins; Esophageal candidiasis; Invasive candidiasis

Indexed keywords

1,3 BETA GLUCAN SYNTHASE; AMPHOTERICIN; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; CASPOFUNGIN; CYCLOSPORIN; ECHINOCANDIN; FLUCONAZOLE; GLUCOCORTICOID; ITRACONAZOLE; KETOCONAZOLE; MICAFUNGIN; RIFAMPICIN; TACROLIMUS; VORICONAZOLE;

AGE DISTRIBUTION; ALANINE AMINOTRANSFERASE LEVEL; ANTIFUNGAL ACTIVITY; AREA UNDER THE CURVE; ASPARTATE AMINOTRANSFERASE LEVEL; ASPERGILLOSIS; ASPERGILLUS; ASPERGILLUS NIDULANS; CANDIDEMIA; CANDIDIASIS; CATHETER INFECTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DOSE RESPONSE; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG COST; DRUG DEGRADATION; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG OVERDOSE; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG STRUCTURE; DRUG SUBSTITUTION; DRUG TOLERABILITY; DYSPNEA; ERYTHEMA; ESOPHAGUS CANDIDIASIS; FACE ERYTHEMA; FLUSHING; FOLLOW UP; GAMMA GLUTAMYLTRANSFERASE LEVEL; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOTENSION; INVASIVE CANDIDIASIS; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; LIVER FAILURE; LIVER FUNCTION; LIVER TOXICITY; LOADING DRUG DOSE; LOW DRUG DOSE; LUNG ASPERGILLOSIS; LUNG TOXICITY; MINIMUM INHIBITORY CONCENTRATION; NAUSEA; NEUTROPENIA; NONHUMAN; OROPHARYNX CANDIDIASIS; PHLEBITIS; PNEUMOCYSTIS JIROVECI; PRURITUS; RANDOMIZED CONTROLLED TRIAL; REVIEW; SEX DIFFERENCE; SIDE EFFECT; SINGLE DRUG DOSE; THROMBOPHLEBITIS; TREATMENT DURATION; TREATMENT RESPONSE; URTICARIA;

ANIMALS; ANTIBIOTICS, ANTIFUNGAL; CANDIDIASIS; CLINICAL TRIALS AS TOPIC; DRUG COSTS; DRUG INTERACTIONS; DRUG RESISTANCE, FUNGAL; ECHINOCANDINS; ESOPHAGEAL DISEASES; HUMANS;

EID: 59949099817     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.29.1.17     Document Type: Review

References (66)

1. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004;39:309-17.
2. Pfizer Inc. Eraxis (anidulafungin) package insert. New York, NY; 2007.
3. Merck & Co. Cancidas (caspofungin acetate for injection) package insert. Whitehouse Station, NJ; 2004.
4. Astellas Pharma, US. Mycamine (micafungin sodium) package insert. Deerfield, IL; 2005.
5. Benjamin DK, Driscoll T, Seibel NL, et al. Safety and pharmacokinetics of intravenous anidulafungin in children with neutropenia at high risk for invasive fungal infections. Antimicrob Agents Chemother 2006; 50:632-8.
6. Walsh T J, Adamson PC, Seibel NL, et al. Pharmacokinetics of caspofungin in pediatric patients [abstract]. In: Program and abstracts of the 42nd interscience conference of antimicrobial agents and chemotherapy. Washington, DC: American Society for Microbiology, 2002:M-896.
7. Seibel NL, Schwartz C, Arrieta A, et al. Safety, tolerability, and pharmacokinetics of micafungin (FK463) in febrile neutropenic pediatric patients. Antimicrob Age nts Chemother 2005; 49:3317-24.
8. Ostrosky-Zeichner L, Kontoyiannis D, Raffalli J, et al. International, open-label, noncomparative, clinical trial of micafungin alone and in combination for treatment of newly diagnosed and refractory candidemia. Eur J Clin Microbiol Infect Dis 2005; 24:654-61.
9. Rhunke M, Kuse E, Chetchotisakd P, da Cuhna CA, Diekmann-Berndt H. Comparison of micafungin and liposomal amphotericin B for invasive candidiasis [abstract]. In: Program and abstracts of the 45 th inte rscience conference of antimicrobial agents and chemotherapy. Washington, DC: American Society for Microbiology, 2005:M-722c.
10. National Institute of Allergy and Infectious Diseases, Division of AIDS. Chemical name: LY303366. Available from http://chemdb2.niaid.nih.gov/ struct-search/all/url-search.asp?aids-no=027813.Accessed January 14, 2008.
11. Debono M, Turner WW, LaGrandeur L, et al. Semisynthetic chemical modification of the antifungal lipopeptide echinocandin B (ECB): structure-activity studies of the lipophilic and geometric parameters of polyarylated acyl analogs of ECB.J Med Chem 1995;38:3271-81.
12. Kurtz MB, Heath IB, Marrinan J, Dreikorn S, Onishi J, Douglas C. Morphological effects of lipopeptides against Aspergillus fumigatus correlate with activities against (1,3)-β-D- glucan synthase. Antimicrob Agents Chemother 1994; 38:1480-9.
13. Nishiyama Y, Uchida K, Yamaguchi H. Morphological changes of Candida albicans induced by micafungin (FK463), a water- soluble echinocandin-like lipopeptide. J Electron Microsc (Tokyo) 2002; 51:247-55.
14. Friesen M, Harding G, Karlowsky J, et al. Antifungal pharmacodynamic activity of the investigational echinocandin LY303366 against fluconazole-sensitive (FLU-S) and fluconazole-resistant (FLU-R) Candida albicans [abstract]. In: Program and abstracts of the 36th interscience conference on antimicrobial agents and chemotherapy. Washington, DC: American Society of Microbiology, 1996:F49.
15. Zhanel GG, Karlowsky JA, Harding GA, et al. In vitro activity of a new semisynthetic echinocandin, LY-303366, against systemic isolates of Candida species, Cryptococcus neoformans, Blastomyces dermatitidis, and Aspergillus species. Antimicrob Agents Chemother 1997; 41:863-5.
16. Stevens DA, Martinez M, Devine MJ. Antifungal activity of LY303366 (LY), an echinocandin beta glucan synthase inhibitor (GSI) [abstract]. In: Program and abstracts of the 36th interscience confe rence on antimicrobial agents and chemothe rapy. Washington, DC: American Society of Microbiology, 1996:F46.
17. Rennie R, Sand C, Smith S. In vitro activity of antifungal agent LY303366 against Candida species, other yeasts and Aspergillus species [ abstract] . In: Program and abstracts of the 36th interscience confe rence on antimicrobial agents and chemothe rapy. Washington, DC: American Society of Microbiology, 1996:F45.
18. Nakai T, Uno J, Ikeda F, Tawara S, Nishimura K, Miyaji M. In vitro antifungal activity of micafungin (FK463) against dimorphic fungi: comparison of yeast-like and mycelial forms. Antimicrob Agents Chemother 2003; 47:1376-81.
19. Pfaller MA, Messer SA, Coffman S. In vitro susceptibilities of clinical yeast isolates to a new echinocandin derivative, LY303366, and other antifungal agents. Antimicrob Agents Chemother 1997; 41:763-6.
20. Padmaja P, Garcia-Effron G, Balashov S, Delmas G, Park S, Perlin DS. Serum differentially alters the antifungal properties of echinocandin drugs. Antimicrob Agents Chemother 2007; 51:2253-6.
21. . Wiederhold NP, Najvar LK, Bocanegra R, Molina D, Olivio M, Graybill JR. In vivo efficacy of anidulafungin and caspofungin against Candida glabrata and association with in vitro potency in the presence of sera. Antimicrob Agents Chemother 2007; 51:1616-20.
22. Schinabeck MK, D'Angelo P, Chandra J, Mukherjee PK, Ghannoum MA. Anidulafungin inhibits Candida albicans biofilms in vitro [abstract]. In: Program and abstracts of the 44th interscience conference on antimicrobial agents and chemotherapy Washington, DC : American Society of Microbiology, 2004:M-1141.
23. Dowell J, Stogniew M, Krause D, Henkel T. Anidulafungin (ANID) pharmacokinetic (PK)/pharmacodynamic (PD) correlation: treatment of esophageal candidiasis (EC) [abstract]. In: Program and abstracts of the 43rd interscience conference on antimicrobial agents and chemotherapy. Washington, DC: American Society of Microbiology, 2003:A-1578.
24. Petraitis V, Petraitiene R, Groll AH, et al. Comparative antifungal activities and plasma pharmacokinetics of micafungin (FK463) against disseminated candidiasis and invasive pulmonary aspergillosis in persistently neutropenic rabbits. Antimicrob Agents Chemother 2002; 46:1857-69.
25. Wiederhold NP, Kontoyiannis DP, Chi J, Prince RA, Tam VH, Lewis RE. Pharmacodynamics of caspofungin in a murine model of invasive pulmonary aspergillosis: evidence of concentration - dependent activity. J In fect Dis 2004 190:1464-71.
26. Andes D, Diekema DJ, Pfaller MA, et al. In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. Antimicrob Agents Chemother 2008; 52:539-50.
27. Park S, Kelly R, Kahn JN, et al. Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp. isolates. Antimicrob Agents Chemother 2005; 49:3264-73.
28. Laverdiere M, Lalonde RG, Baril JG, Sheppard DC, Park S, Perlin DS. Progressive loss of echinocandin activity following prolonged use for treatment of Candida albicans oesophagitis. J Antimicrob Chemother 2006; 57:705-8.
29. Stevens DA, Ichinomiya M, Koshi Y, Horiuchi H. Escape of Candida from caspofungin inhibition at concentrations above the MIC (paradoxical effect) accomplished by increased cell wall chitin: evidence for β-1,6-glucan synthesis inhibition by caspofungin. Antimicrob Agents Chemother 2006; 50:3160-1.
30. Wiederhold NR, Kontoyiannis DP, Prince RA, Lewis RE. Attenuation of the activity of caspofungin at high concentrations against Candida albicans: possible role of cell wall integrity and calcineurin pathways. Antimicrob Agents Chemother 2005; 49:5146-8.
31. Chamilos G, Lewis RE, Albert N, Kontoyiannis DP. Paradoxical effect of echinocandins across Candida species in vitro: evidence for echinocandin-specific and candida species- related differences. Antimicrob Agents Chemother 2007; 51:2257-9.
32. Petraitis V, Petraitiene R, Hope W, et al. Combination therapy of voriconazole and anidulafungin improves outcome of experimental pulmonary aspergillosis [abstract]. In: Program and abstracts of the 46th interscience conference on antimicrobial agents and chemotherapy. Washington, DC: American Society of Microbiology, 2006:M-882.
33. Petraitiene R, Petraitis V, Groll A, et al. Antifungal efficacy of caspofungin ( MK-0991 ) in experimental pulmonary aspergillosis in persistently neutropenic rabbits: pharmacokinetics, drug disposition, and relationship to galactomannan antigenemia. Antimicrob Agents Chemother 2002; 46:12-23.
34. Groll AH, Mickiene D, Petraitiene R, et al. Pharmacokinetic and pharmacodynamic modeling of anidulafungin (LY303366): reappraisal of its efficacy in neutropenic animal models of opportunistic mycoses using optimal plasma sampling. Antimicrob Agents Chemother 2001; 45:2845-55.
35. Petraitiene R, Petraitis V, Groll AH, et al. Antifungal activity of LY303366, a novel echinocandin B, in experimental disseminated candidiasis in rabbits. Antimicrob Agents Chemother 1999; 43:2148-55.
36. Lucas R, Desante K, Hatcher B, et al. LY303366 Single dose pharmacokinetics and safety in healthy male volunteers [abstract]. In: Program and abstracts of the 36th interscience conference on antimicrobial agents and chemotherapy. Washington, DC: American Society of Microbiology, 1996:F50.
37. Dowell J, Pu F, Lee J, Stogniew M, Krause D, Henkel T. A clinical mass balance study of anidulafungin (ANID) showing complete fecal elimination [abstract]. In: Program and abstracts of the 43rd interscience conference on antimicrobial agents and chemotherapy. Washington, DC: American Society of Microbiology, 2003:A-1576.
38. Dowell JA, Knebel W, Ludden T, Stogniew M, Krause D, Henkel T. Population pharmacokinetic analysis of anidulafungin, an echinocandin antifungal. J Clin Pharmacol 2004; 44:590-8.
39. Stone JA, Holland SD, Wickersham PJ, et al. Single- and multiple-dose pharmacokinetics of caspofungin in healthy men. Antimicrob Agents Chemother 2002; 46:739-45.
40. Denning DW. Echinocandin antifungal drugs. Lancet 2003; 362:1142-51.
41. . Thye D, Kilfoil T, White RJ, Lasseter K. Anidulafungin: pharmacokinetics in subjects with mild and moderate hepatic impairment [abstract]. In: Program and abstracts of the 41st interscience conference on antimicrobial agents and chemotherapy. Washington, DC: American Society of Microbiology, 2001:A-34.
42. Thye D, Kilfoil T, Kilfoil G, Henkel T. Anidulafungin: pharmacokinetics (PK) in subjects with severe hepatic impairment (HI) [abstract]. In: Program and abstracts of the 42nd interscience conference on antimicrobial agents and chemotherapy. Washington, DC: American Society of Microbiology, 2002:A-1392.
43. Thye D, Marbury T, Kilfoil G, Kilfoil T, Henkel T. Anidulafungin: pharmacokinetics in subjects with renal impairment [abstract]. In: Program and abstracts of the 42nd interscience conference on antimicrobial agents and chemotherapy. Washington, DC: American Society of Microbiology, 2002:A-1391.
44. Thye D, Marbury T, Kilfoil T, Kilfoil G, Henkel T. Anidulafungin: pharmacokinetics in subjects receiving hemodialysis [abstract]. In: Program and abstracts of the 42nd interscience conference on antimicrobial agents and chemotherapy. Washington, DC: American Society of Microbiology, 2002:A-1390.
45. . White RJ, Thye D. Anidulafungin does not affect the metabolism of cyclosporin by human hepatic microsomes [abstract]. In: Program and abstracts of the 41st interscience conference on antimicrobial agents and chemotherapy. Washington, DC: American Society of Microbiology, 2001:A-35.
46. Thye D, Kilfoil T, Kilfoil G, Henkel T. Anidulafungin: safety and pharmacokinetics in subjects receiving concomitant cyclosporine [abstract]. In: Program and abstracts of the 42nd interscience conference on antimicrobial agents and chemotherapy. Washington, DC: American Society of Microbiology, 2002:A-1836.
47. Dowell JA, Stogniew M, Krause D, Henkel T, Damle B. Lack of pharmacokinetic interaction between anidulafungin and tacrolimus. J Clin Pharmacol 2007; 47:305-14.
48. Petraitis V, Petraitiene R, Groll AH, et al. Antifungal efficacy, safety, and single-dose pharmacokinetics of LY303366, a novel echinocandin B, in experimental pulmonary aspergillosis in persistently neutropenic rabbits. Antimicrob Agents Chemother 1998; 42:2898-905.
49. Roberts J, Schock K, Marino S, Andriole VT. Efficacies of two new antifungal agents, the triazole ravuconazole and the echinocandin LY-303366, in an experimental model of invasive aspergillosis. Antimicrob Agents Chemother 2000; 44:3381-8.
50. Najvar LK, Bocanegra R, Sanche SE, Graybill JR. Efficacy of LY303366 (LY) in mice with itraconazole (ITRA)-resistant aspergillosis [abstract]. In: Program and abstracts of the 39th interscience conference on antimicrobial agents and chemotherapy. Washington, DC: American Society of Microbiology, 1999:2002.
51. Gumbo T, Louie A, Liu W, Deziel M, Drusano MF, Drusano GL. Relative efficacies of anidulafungin, fluconazole, and amphotericin B for treatment of disseminated Candida glabrata in neutropenic mice [abstract]. In: Program and abstracts of the 43rd interscience conference on antimicrobial agents and chemotherapy. Washington, DC: American Society of Microbiology, 2003:A-1577.
52. Brown GI, White RJ, Turik M. Phase II, randomized, open label study of two intravenous dosing regimens of V- echinocandin in the treatment of esophageal candidiasis [abstract]. In: Program and abstracts of the 40th interscience conference on antimicrobial agents and chemotherapy. Washington, DC: American Society of Microbiology, 2000;1106.
53. Krause DS, Simjee AE, van Rensburg C, et al. A randomized, double-blind trial of anidulafungin versus fluconazole for the treatment of esophageal candidiasis. Clin Infect Dis 2004;39:770-5.
54. 4. Viljoen J, Schranz JA, Krause D, Simjee A, Van Rensburg C, Walsh TJ. Clinical efficacy results from a phase 3 study of anidulafungin (ANID) versus fluconazole (FLU) in HIV negative patients with esophageal candidiasis (EC). In: Program and abstracts of the 44th interscience conference on antimicrobial agents and chemotherapy. Washington, DC: American Society ofMicrobiology, 2004:M-1023.
55. Vazquez J A, Schranz J, Krause D, et al. Efficacy of anidulafungin (ANID) in patients (Pts) with azole-refractory mucosal candidiasis (ARMC) [ abstract] . In: Program and abstracts of the 44th interscience conference on antimicrobial agents and chemotherapy. Washington, DC: American Society of Microbiology, 2004:M-1038.
56. Petraitis V, Petraitiene R, Groll AH, et al. Dosage-dependent antifungal efficacy of V-echinocandin (LY303366) against experimental fluconazole-resistant oropharyngeal and esophageal candidiasis. Antimicrob Agents Chemother 2001; 45:471-9.
57. Krause DS, Reinhardt J, Vazquez JA, et al. Phase 2,randomized, dose-ranging study evaluating the safety and efficacy of anidulafungin in invasive candidiasis and candidemia. Antimicrob Agents Chemother 2004; 48:2021-4.
58. Betts R, Kett D, Clark K, Schlamm HT, Krause DS. An open- label study of anidulafungin in invasive candidiasis and candidemia [abstract]. Clin Microbiol Infect 2006; 12(suppl 4):P1205.
59. Reboli AC, Rotstein C, Pappas PG, et al. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med 2007; 356:2472-82.
60. Thye D, Shepherd B, White RJ, Weston IE, Henkel T. Anidulafungin: a phase 1 study to identify the maximum tolerated dose in healthy volunteers [abstract]. In: Program and abstracts of the 41st interscience conference on antimicrobial agents and chemotherapy. Washington, DC: American Society of Microbiology, 2001:A-36.
61. Karlowsky JA, Hoban DJ, Zhanel GG, Goldstein BP. In vitro interactions of anidulafungin with azole antifungals, amphotericin B and 5-fluorocytosine against Candida species. Int J Antimicrob Agents 2006; 27:174-7.
62. Philip A, Odabasi Z, Rodriguez J, et al. In vitro synergy testing of anidulafungin with itraconazole, voriconazole, and amphotericin B against Aspergillus spp. and Fusarium spp. Antimicrob Agents Chemother 2005; 49:3572-4.
63. Meletiadis J, Stergiopoulou V, Petraitis V, et al. In vitro and in vivo correlation of the synergistic interaction between voriconazole (VRC) and anidulafungin (AFG) against Aspergillus fumigatus using the bliss independence drug interaction (BIDI) analysis [abstract]. In: Program and abstracts of the 47th interscience conference on antimicrobial agents and chemotherapy. Washington, DC: American Society of Microbiology, 2007;M-740.
64. Marr KA, Boeckh M, Carter RA, Kim HW, Corey L. Combination antifungal therapy for invasive aspergillosis. Clin Infect Dis 2004; 39:797-802.
65. Singh N, Limaye AP, Forrest G, et al. Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients: a prospective, multicenter, observational study. Transplantation 2006; 81:320-6.
66. Dowell JA, Schranz J, Baruch A, Foster G. Safety and pharmacokinetics of coadministered voriconazole and anidulafungin. J Clin Pharmacol 2005; 45:1373-82.